Croatia

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical &... 2011-01-13

BMI View: In order to ensure timely and efficient marketing authorisation for imported medicines and to ensure Croatian pharmaceutical export growth is maintained, BMI believes that... 2011-01-11

BMI View: The introduction of a promotion fund paid directly to Croatia's Health Insurance Institute (HZZO) will not be welcomed by pharmaceutical companies operating in the country.... 2011-01-06

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has declined. The region scored 51.5 out of 100 in BMI's Pharmaceutical &... 2010-10-27

BMI has introduced greater clarity to its core views for the Pharmaceuticals & Healthcare. Short-term core views concern the period through to the end of the 2011-2013 patent cliff,... 2010-03-15

BMI forecasts that pharmaceutical sales in Emerging Europe will grow by 125% over the next decade, representing a compound annual growth rate (CAGR) of 8.43%. With global sales projected... 2010-01-05

BMI's regional outlook for pharmaceutical companies in Emerging Europe has improved marginally, following an update to our Pharmaceuticals & Healthcare Business Environment Ratings.... 2009-10-30